UPLOAD Filing
DiaMedica Therapeutics Inc.
Date: Aug. 5, 2025 · CIK: 0001401040 · Accession: 0000000000-25-008250
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289159
Letter
Re: DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed August 1, 2025 File No. 333-289159 Dear Scott Kellen:
August 5, 2025
Scott Kellen Chief Financial Officer DiaMedica Therapeutics Inc. 301 Carlson Parkway, Suite 210 Minneapolis, MN 55305
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Matthew W. Mamak, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 5, 2025 Scott Kellen Chief Financial Officer DiaMedica Therapeutics Inc. 301 Carlson Parkway, Suite 210 Minneapolis, MN 55305 Re: DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed August 1, 2025 File No. 333-289159 Dear Scott Kellen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew W. Mamak, Esq. </TEXT> </DOCUMENT>